Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2022-01-30 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Updated Investor Presentation 20 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is titled 'Investor Presentation | 31 January 2022' and contains detailed information about Pharmaxis' clinical stage drug development programs, pipeline assets, market opportunities, clinical trial designs, financial snapshot, and anticipated news flow. It includes forward-looking statements, executive summary, clinical data, commercial opportunities, and strategic plans. The content is structured as a presentation aimed at investors, focusing on financials, strategy, and market position rather than being a formal regulatory filing or financial report. There is no indication that this is an annual report, earnings release, or regulatory filing. The length (15,000 characters) and detailed content support that this is a full investor presentation document rather than a brief announcement or summary. Therefore, the appropriate classification is Investor Presentation (IP).
2022-01-30 English
PXS Quarterly Shareholder Update and Investor Briefing 2 pages 126.9KB
Investor Presentation Classification · 95% confidence The document is titled 'PHARMAXIS QUARTERLY SHAREHOLDER UPDATE AND INVESTOR BRIEFING' and mentions a quarterly update release date and an investor briefing event with a presentation and Q&A session. It is a communication about a quarterly progress update and future plans, typical of an investor presentation or briefing. The document does not contain actual financial statements or detailed financial analysis, but rather an announcement and invitation to a briefing event. Therefore, it fits best as an Investor Presentation (IP) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2022-01-26 English
Response to ASX Aware Query 7 pages 404.4KB
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from Pharmaxis Limited to the Australian Securities Exchange (ASX) regarding an ASX query about a prior announcement made by Pharmaxis. The letter addresses compliance with ASX Listing Rules, specifically Listing Rule 3.1 about continuous disclosure obligations and price sensitivity of information. It discusses the nature of the announcement, timing of disclosure, and the company's internal approval process for the response. The document is a regulatory compliance communication and does not contain financial statements, earnings data, or management discussion of financial results. It is not a report itself but a regulatory filing responding to a compliance query from the exchange. Therefore, it fits best under the category of Regulatory Filings (RNS).
2022-01-09 English
PXS Collaborators Receive Government Grants of $1.4m 3 pages 156.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 6 January 2022 from Pharmaxis Ltd announcing government grants awarded to scientific collaborators for drug development research. It discusses research funding, collaborations, and drug development progress but does not contain financial statements, earnings data, or detailed financial analysis. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing, board change, or voting result announcement. The content is a corporate announcement about research grants and collaborations, which fits best under the category of a general regulatory announcement or miscellaneous corporate news. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (9585 characters) and content confirm it is not a brief report publication announcement or a certification letter.
2022-01-05 English
Change of Director's Interest Notice 2 pages 149.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares disposed and acquired, nature of the transaction, and dates. This is a formal notification of personal share transactions by a company director. The document length is 3735 characters, which is typical for such notices. There is no financial performance data, earnings information, or management discussion. Therefore, this document fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades).
2021-12-23 English
Change of Director's Interest Notice 3 pages 147.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including the number of shares acquired, disposed, and held after the change. This is a report of personal share transactions by a company director. The document length is 3481 characters, which is typical for such notices. There is no indication that this is a full financial report or an announcement of a report publication. Therefore, the document fits the definition of 'Director's Dealing' (DIRS).
2021-12-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.